Quinupristin-Dalfopristin and Linezolid: Evidence and Opinion

摘要: Quinupristin-dalfopristin and linezolid demonstrate in vitro activity against a wide range of gram-positive bacteria, including many isolates resistant to earlier antimicrobials. is inactive Enterococcus faecalis but has been effective for treatment infections due vancomycin-resistant faecium associated with bacteremia. In comparative trials, proved be equivalent comparator agents, resulting its approval several clinical indications. The almost-complete bioavailability permits oral administration. Each agent can cause adverse effects that may limit use individual patients. Resistance these drugs encountered infrequently among E. faecium. quinupristin-dalfopristin rare staphylococci the United States, resistance very rare. Whether there any benefit agents combination regimens, whether are circumstances which they might alternatives cell-wall active antibiotics bone or endovascular infections, questions deserve further study.